Key result
Hemodialysis linked to ~43% reduction in plasma endothelin-1 in ESRD.
Why the study?
End-stage renal disease involves multiple organs including the lungs, and changes in pulmonary function and plasma endothelin-1 levels after hemodialysis are not well characterized.
Does hemodialysis improve pulmonary function tests and alter plasma endothelin-1 levels in patients with end-stage renal disease?
Population
20 patients with end-stage renal disease
Comparison
Before hemodialysis vs after hemodialysis
Design
Cross-sectional study
Follow-up
Immediate (before and after a single hemodialysis session)
Authors
Loading...
Observed post-HD lung function gains and ET-1 drop in ESRD are hypothesis-generating; larger prospective studies needed before clinical adoption.
Cross-Sectional (n=20)
Does hemodialysis improve pulmonary function tests and alter plasma endothelin-1 levels in patients with end-stage renal disease?
Absolute Event Rate: 3.91% vs 6.88%
p-value: p=0.009
Hemodialysis significantly reduces plasma endothelin-1 levels, which is associated with improvements in spirometric parameters in patients with end-stage renal disease.
Noshad et al. (2014) conducted a cross-sectional in End-stage renal disease (ESRD) (n=20). Hemodialysis vs. Before hemodialysis was evaluated on Plasma endothelin-1 (ET-1) levels (p=0.009). Hemodialysis significantly decreased plasma endothelin-1 levels from 6.88 pg/mL to 3.91 pg/mL (P=0.009) in patients with end-stage renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: